|
1
|
Lam WK and Watkins DN: Lung cancer: future
directions. Respirology. 12:471–477. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kishimoto T, Akira S, Narazaki M and Taga
T: Interleukin-6 family of cytokines and gp130. Blood.
86:1243–1254. 1995.PubMed/NCBI
|
|
3
|
Hodge DR, Hurt EM and Farrar WL: The role
of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer.
41:2502–2512. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Michalaki V, Syrigos K, Charles P and
Waxman J: Serum levels of IL-6 and TNF-alpha correlate with
clinicopathological features and patient survival in patients with
prostate cancer. Br J Cancer. 90:2312–2316. 2004.PubMed/NCBI
|
|
5
|
Plante M, Rubin SC, Wong GY, Federici MG,
Finstad CL and Gastl GA: Interleukin-6 level in serum and ascites
as a prognostic factor in patients with epithelial ovarian cancer.
Cancer. 73:1882–1888. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang GJ and Adachi I: Serum interleukin-6
levels correlate to tumor progression and prognosis in metastatic
breast carcinoma. Anticancer Res. 19:1427–1432. 1999.PubMed/NCBI
|
|
7
|
Chung YC and Chang YF: Serum interleukin-6
levels reflect the disease status of colorectal cancer. J Surg
Oncol. 83:222–226. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ohsugi Y and Kishimoto T: The recombinant
humanized anti-IL-6 receptor antibody tocilizumab, an innovative
drug for the treatment of rheumatoid arthritis. Expert Opin Biol
Ther. 8:669–681. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bongartz T: Tocilizumab for rheumatoid and
juvenile idiopathic arthritis. Lancet. 371:961–963. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kudo M, Jono H, Shinriki S, Yano S,
Nakamura H, Makino K, Hide T, Muta D, Ueda M, Ota K, et al:
Antitumor effect of humanized anti-interleukin-6 receptor antibody
(tocilizumab) on glioma cell proliferation. Laboratory
investigation. J Neurosurg. 111:219–225. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Haura EB, Livingston S and Coppola D:
Autocrine interleukin-6/interleukin-6 receptor stimulation in
non-small-cell lung cancer. Clin Lung Cancer. 7:273–275. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yi H, Cho HJ, Cho SM, Jo K, Park JA, Kim
NH, Amidon GL, Kim JS and Shin HC: Blockade of interleukin-6
receptor suppresses the proliferation of H460 lung cancer stem
cells. Int J Oncol. 41:310–316. 2012.PubMed/NCBI
|
|
13
|
Koyama Y, Mitsui N, Suzuki N, Yanagisawa
M, Sanuki R, Isokawa K, Shimizu N and Maeno M: Effect of
compressive force on the expression of inflammatory cytokines and
their receptors in osteoblastic Saos-2 cells. Arch Oral Biol.
53:488–496. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jiang XP, Yang DC, Elliott RL and Head JF:
Down-regulation of expression of interleukin-6 and its receptor
results in growth inhibition of MCF-7 breast cancer cells.
Anticancer Res. 31:2899–2906. 2011.PubMed/NCBI
|
|
15
|
Yao X, Huang J, Zhong H, Shen N, Faggioni
R, Fung M and Yao Y: Targeting interleukin-6 in inflammatory
autoimmune diseases and cancers. Pharmacol Ther. 141:125–139. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fizazi K, De Bono JS, Flechon A,
Heidenreich A, Voog E, Davis NB, Qi M, Bandekar R, Vermeulen JT,
Cornfeld M and Hudes GR: Randomised phase II study of siltuximab
(CNTO 328), an anti-IL-6 monoclonal antibody, in combination with
mitoxantrone/prednisone versus mitoxantrone/prednisone alone in
metastatic castration-resistant prostate cancer. Eur J Cancer.
48:85–93. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hunsucker SA, Magarotto V, Kuhn DJ,
Kornblau SM, Wang M, Weber DM, Thomas SK, Shah JJ, Voorhees PM, Xie
H, et al: Blockade of interleukin-6 signalling with siltuximab
enhances melphalan cytotoxicity in preclinical models of multiple
myeloma. Br J Haematol. 152:579–592. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hsu CP, Chen YL, Huang CC, Chou CC, Liu
CL, Hung CH, Kao TY and Chung YC: Anti-interleukin-6 receptor
antibody inhibits the progression in human colon carcinoma cells.
Eur J Clin Invest. 41:277–284. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Schneider MR, Hoeflich A, Fischer JR, Wolf
E, Sordat B and Lahm H: Interleukin-6 stimulates clonogenic growth
of primary and metastatic human colon carcinoma cells. Cancer Lett.
151:31–38. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yilmaz S and Simsek I: Early intervention
in the treatment of rheumatoid arthritis: focus on tocilizumab.
Ther Clin Risk Manag. 9:403–408. 2013.PubMed/NCBI
|
|
21
|
Oldfield V, Dhillon S and Plosker GL:
Tocilizumab: a review of its use in the management of rheumatoid
arthritis. Drugs. 69:609–632. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Klein B, Wijdenes J, Zhang XG, Jourdan M,
Boiron JM, Brochier J, Liautard J, Merlin M, Clement C,
Morel-Fournier B, et al: Murine anti-interleukin-6 monoclonal
antibody therapy for a patient with plasma cell leukemia. Blood.
78:1198–1204. 1991.PubMed/NCBI
|
|
23
|
Sato K, Tsuchiya M, Saldanha J, Koishihara
Y, Ohsugi Y, Kishimoto T and Bendig MM: Reshaping a human antibody
to inhibit the interleukin 6-dependent tumor cell growth. Cancer
Res. 53:851–856. 1993.PubMed/NCBI
|
|
24
|
Stärkel P, Charette N, Borbath I,
Schneider-Merck T, De Saeger C, Abarca J, Leclercq I and Horsmans
Y: Ras inhibition in hepatocarcinoma by
S-trans-trans-farnesylthiosalicyclic acid: association of its tumor
preventive effect with cell proliferation, cell cycle events and
angiogenesis. Mol Carcinog. 51:816–825. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sorriento D, Illario M, Finelli R and
Iaccarino G: To NFκB or not to NFκB: The Dilemma on How to Inhibit
a Cancer Cell Fate Regulator. Transl Med UniSa. 4:73–85.
2012.PubMed/NCBI
|
|
26
|
Chang TP and Vancurova I: NFκB function
and regulation in cutaneous T-cell lymphoma. Am J Cancer Res.
3:433–445. 2013.PubMed/NCBI
|
|
27
|
Martin AG: NFκB anti-apoptotic or
pro-apoptotic, maybe both. Cell Cycle. 9:3131–3132. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Viatour P, Merville MP, Bours V and
Chariot A: Phosphorylation of NF-kappaB and IkappaB proteins:
implications in cancer and inflammation. Trends Biochem Sci.
30:43–52. 2005. View Article : Google Scholar : PubMed/NCBI
|
